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CaMKII has been shown to be activated during different cardiac pathological processes,
and CaMKII-dependent mechanisms contribute to pathological cardiac remodeling, cardiac
arrhythmias, and contractile dysfunction during heart failure. Activation of CaMKII during
cardiac stress results in a broad number of biological effects such as, on the one
hand, acute effects due to phosphorylation of distinct cellular proteins as ion channels
and calcium handling proteins and, on the other hand, integrative mechanisms by
changing gene expression. This review focuses on transcriptional and epigenetic effects
of CaMKII activation during chronic cardiac remodeling. Multiple mechanisms have been
described how CaMKII mediates changes in cardiac gene expression. CaMKII has been
shown to directly phosphorylate components of the cardiac gene regulation machinery.
CaMKII phosphorylates several transcription factors such as CREB that induces the
activation of specific gene programs. CaMKII activates transcriptional regulators also
indirectly by phosphorylating histone deacetylases, especially HDAC4, which in turn
inhibits transcription factors that drive cardiac hypertrophy, fibrosis, and dysfunction.
Recent studies demonstrate that CaMKII also phosphorylate directly histones, which
may contribute to changes in gene expression. These findings of CaMKII-dependent
gene regulation during cardiac remodeling processes suggest novel strategies for
CaMKII-dependent “transcriptional or epigenetic therapies” to control cardiac gene
expression and function. Manipulation of CaMKII-dependent signaling pathways in the
settings of pathological cardiac growth, remodeling, and heart failure represents an
auspicious therapeutic approach.
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INTRODUCTION
Heart failure is the leading cause of death in developed countries
and is characterized by adverse cardiac remodeling upon patho-
logical stress situations such as arterial hypertension, ischemic
injuries or due to genetic causes. Adverse left ventricular remodel-
ing is usually described by a combination of myocardial hypertro-
phy, cell death, interstitial fibrosis and an activation of a so-called
fetal gene program (Koitabashi and Kass, 2012). Calcium-
dependent signaling pathways including Calcium/Calmodulin-
dependent kinase II (CaMKII) signaling play pivotal roles in
adverse cardiac remodeling (Heineke and Molkentin, 2006; Bers,
2008; Backs et al., 2009; Ling et al., 2009). Activation of CaMKII
during cardiac stress results in a broad number of biological
effects. On the one hand, CaMKII mediates immediate effects
due to phosphorylation of cellular proteins such as ion chan-
nels and calcium handling proteins (Anderson et al., 2011). On
the other hand, CaMKII affects structural features of the cardiac
phenotype due to phosphorylation of proteins of the transcrip-
tional machinery (Anderson et al., 2011). This review focuses on
CaMKII-dependent transcriptional and epigenetic mechanisms
that occur in cardiomyocytes during pathological and physiologi-
cal processes. First, we will review the different CaMKII genes and
splice variants that localize to different subcellular compartments.
CaMKII ISOFORMS AND SPLICE VARIANTS
In 2003, Colomer and colleagues observed an increased activ-
ity of Calcium/Calmodulin-dependent kinases upon patho-
logical pressure overload due to transverse aortic constric-
tion (TAC), and they described the expression patterns of
the Calcium/Calmodulin-dependent kinases CaMKI, CaMKII,
and CaMKIV (Colomer et al., 2003). They found CaMKI
to be expressed in left ventricular tissue, but not up-
regulated upon TAC. Whereas artificial overexpression of
CaMKIV in a transgenic model was sufficient to induce car-
diac hypertrophy in another study (Passier et al., 2000), in
the model of Colomer, left ventricular CaMKIV was not
detectable, and mice lacking CaMKIV did not display an
altered response to TAC, indicating that CaMKIV is not
required for cardiac hypertrophy. They convincingly demon-
strated that CaMKII is the only multifunctional CaMK that is
not only up-regulated on the expression level but also activated
after TAC.
CaMKII consists of four different isoforms with distinct
expression patterns. CaMKIIα and CaMKIIβ are enriched in
neuronal tissue, and CaMKIIδ, and CaMKIIγ are expressed ubiq-
uitously (Hudmon and Schulman, 2002). CaMKIIδ is the most
abundant cardiac CaMKII isoform but CaMKIIγ is also expressed
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in the heart (Hoch et al., 1999; Colomer et al., 2003). The
first in vivo studies establishing CaMKII as a potential target
for cardiac arrhythmias and structural heart disease were con-
ducted by the use of a pharmacological inhibitor such as KN-62
or KN-93 and a CaMKII inhibitory peptide (Zhang et al., 2005;
Vila-Petroff et al., 2007; Liu et al., 2011). Due to the unclear role
of the single CaMKII isoforms and potential unspecific effects
of CaMKII inhibitors, isoform-specific genetic loss of function
models were generated. Mice with a global deletion of CaMKIIδ
were protected against adverse cardiac remodeling (Backs et al.,
2009; Ling et al., 2009). CaMKIIδ global knockout mice produced
by us were protected from cardiac fibrosis and hypertrophy 3
weeks after TAC surgery. CaMKIIδ global knockout model gen-
erated by Ling and colleagues were protected from fibrosis and
dysfunction. These mice were not protected from cardiac hyper-
trophy 2 weeks but only 6 weeks after TAC. These seemingly
different phenotypes with regard to cardiac hypertrophy may
be explained by different surgery techniques, different genetic
backgrounds, or different knockout strategies. With regard to
the latter, in the first model, no residual protein was expressed
(transcriptional null due to deletion of exon 1 and 2), whereas
in the second model the possible existence of a truncated pro-
tein encoding a region before exon 8 was not ruled out (exons
9–11 were deleted). The specific role of cardiac CaMKIIγ and
a potential redundancy with CaMKIIδ have not been investi-
gated yet. In human and experimental heart failure, enhanced
CaMKII activity was mainly attributed to an enhanced expres-
sion of the CaMKIIδ splice variants CaMKIIδB and CaMKIIIδC
(Edman and Schulman, 1994; Hoch et al., 1999). From transgenic
mouse models with artificial overexpression of these splice vari-
ants it was concluded that CaMKIIδB (localizes to the nucleus)
promotes cardiac hypertrophy and CaMKIIδC (localizes to the
cytosol) results in dilated cardiomyopathy, respectively (Zhang
et al., 2002b, 2003). Moreover, CaMKIIδA (localizes to sarcolem-
mal and nuclear membranes) was implied as another splice
variant that is regulated at least in a model of cardiac hypertro-
phy due to isoproterenol treatment in mice (Xu et al., 2005; Li
et al., 2011). However, to our knowledge transgenic models of
CaMKIIδA have not been generated so far. An overview of avail-
able genetic mouse models related to cardiac CaMKII is given in
Table 1.
CaMKII AND TRANSCRIPTIONAL REGULATION
Effects of CaMKII on cardiac gene expression was first reported
by the group of Joan Heller Brown when transient expression
of CaMKIIδB in neonatal rat ventricular myocytes induced gene
expression of atrial natriuretic factor (ANF) and resulted in
enhanced transcriptional activation of an ANF-luciferase reporter
gene (Ramirez et al., 1997). As we know now, CaMKII is involved
in the regulation of many transcription factors such as the activa-
tion protein-1 (AP-1) (Antoine et al., 1996), activating transcrip-
tion factor-1 (ATF-1) (Shimomura et al., 1996), serum response
factor (SRF) (Fluck et al., 2000), cAMP-response element binding
protein (CREB) (Sun et al., 1994), and myocyte enhancer fac-
tor 2 (MEF2). The latter is discussed in the next paragraph. An
overview about the identified transcriptional regulators is given
in Figure 1.
A well-known transcription factor in striated muscle biology is
SRF, and Calcium/Calmodulin-dependent regulation of SRF via
interaction with CaMKIV and histone deacetylase 4 (HDAC4),
but not CaMKII, was demonstrated to be involved in the devel-
opment of cardiac hypertrophy (Davis et al., 2003). A direct
phosphorylation of SRF by CaMKII has been shown in skeletal
muscle at Ser-103 and Thr-160 (Fluck et al., 2000), but its rel-
evance in cardiomyocytes remains unclear. However, data from
other cell types indicate that SRF-dependent gene transcription
might depend on phosphorylation by CaMKII (Ely et al., 2011).
As genetic animal models provide evidence for an important role
for SRF in the induction and maintenance of the cardiac myo-
genic program (Lin et al., 1997; Parlakian et al., 2005; Backs
et al., 2011), a better understanding of CaMKII-dependent SRF
regulation is urgently needed.
AP-1 elements are a group of transcription factors com-
posed of either homodimers of the Jun family (c-Jun, JunB,
and JunD) or heterodimers of the Fos and Jun families (c-
Fos, Fra-1, Fra-2, and FosB) (Mechta-Grigoriou et al., 2001).
There is evidence for CaMKII-dependent transcriptional activity
via AP-1 in non-cardiac tissues (Mishra et al., 2005; Zayzafoon
et al., 2005). Recently, CaMKII-dependent upregulation of the
sodium/calcium exchanger 1 (NCX1) has been shown to depend
on AP-1 transcription factors c-Jun and JunB in cardiomyocytes
(Mani et al., 2010). However, it remains unclear whether CaMKII
phosphorylates AP-1 elements directly or indirectly.
Table 1 | Genetic mouse models for CaMKIIδ and γ.
Gene/splicing Type Strategy Cardiac phenotype Location References
variant
CaMKIIδB Gain of function αMHC-driven transgene Cardiac hypertrophy Nucleus Zhang et al., 2002b
CaMKIIδC Gain of function αMHC-driven transgene Dilated cardiomyopathy Cytosol Zhang et al., 2003
CaMKIIδ Loss of function Global knockout exons 9–11 Protection from fibrosis, dysfunction,
and late hypertrophy
Nucleus/Cytosol Ling et al., 2009
CaMKIIδ Loss of function Global knockout exons 1–2 Protection from early hypertrophy and
fibrosis
Nucleus/Cytosol Backs et al., 2009
CaMKIIγ Loss of function Global knockout exons 1–2 Not investigated Nucleus/Cytosol Backs et al., 2010
Cardiomyocyte-specific transgenic overexpression of CaMKIIδ (splice variants B and C) are driven by the αMHC promoter. Global knockout models for CaMKIIδ were
generated by two labs. The second cardiac CaMKII isoform, CaMKIIγ , has so far not been investigated with regard to cardiac stress situations.
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FIGURE 1 | Schematic of transcription factors and transcriptional
repressors regulated by CaMKII in cardiomyocytes. CaMKII
phosphorylates HDAC4 at Ser-467 and Ser-632, allowing binding of the
chaperone protein 14-3-3, leading to nucleo-cytoplasmic shuttling of a
phospho-HDAC4/14-3-3 complex out of the nucleus and resulting in
derepression of transcription factors such as MEF2 that regulates genes
responsible for adverse cardiac remodeling. Other transcription factors such
as NF-κB or HSP-1 may play maladaptive or adaptive roles and these factors
can be directly or indirectly regulated by CaMKII. Another transcription factor
regulated after β-adrenergic stimulation is CREB that can be phosphorylated
by CaMKII at two serine residues, Ser-133 and Ser-142, resulting in opposing
effects in regard to activation of CREB. However, the functional effects of
CREB/CaMKII interaction during cardiac remodeling remain unclear. Another
recently recognized mechanism is translocation of the transcriptional
repressor DREAM from the cytosol to the nucleus. Calcineurin/NFAT
interaction may also be inhibited by direct phosphorylation by CaMKII at
Ser-411, leading to decreased NFAT translocation to the nucleus and
subsequent reduced transcriptional activity. AP-1 activation protein-1, ATF-1
activating transcription factor-1, CaMKII Calcium/Calmodulin-dependent
kinase II, CREB cAMP-response element binding protein, DREAM
downstream regulatory element agonist modulator, HDAC4 histone
deacetylase 4, HSF-1 heat shock factor 1, MEF2 myocyte elongation factor,
NFAT nuclear factor of activated T-cells, NF-κB nuclear factor κB, and SRF
serum response factor.
As one of the well characterized transcription factors activated
by G-protein coupled receptors, CREB has been shown to
be phosphorylated by Calcium/Calmodulin-dependent kinases
(Sheng et al., 1991). Several phosphorylation sites in CREB have
been identified to regulate transcriptional activity and have been
shown to be regulated by CaMKII in a dual way. Phosphorylation
of CREB at Ser-133 by PKA and CaMKII is required for
CREB activation, whereas phosphorylation of Ser-142 by CaMKII
inhibits CREB activity by inhibition of CREB dimerization and
protein/protein interactions that are necessary to form an active
promoter complex (Wu and McMurray, 2001). In vitro stud-
ies using purified CaMKIV and CaMKII have demonstrated that
CaMKIV phosphorylates CREB on Ser-133, whereas CaMKII has
equal affinity for Ser-133 and Ser-142 (Sun et al., 1994). However,
whereas nuclear calcium elevations increase CREB-dependent
transcriptional activity (Kobrinsky et al., 2011), it remains unclear
whether CaMKII-dependent CREB phosphorylation plays a sig-
nificant role in cardiac remodeling processes (Li et al., 2006).
Another member of the cAMP-responsive transcription factor
family is ATF-1. ATF-1 is phosphorylated at Ser-63 by CaMKII,
increasing its transcriptional activity (Shimomura et al., 1996),
but the relevance of ATF-1 activity in cardiomyocytes is unknown.
Studies using KN-93, a CaMKII-inhibitory chemical com-
pound, postulated CaMKII-dependent activation of transcription
factor nuclear factor-κB (NF-κB) leading to cardiomyocyte hyper-
trophy (Kashiwase et al., 2005). In CaMKIIδ knockout mouse
studies, NF-κB-dependent mechanisms and subsequent activa-
tion of inflammatory genes were found to play a maladaptive
role in myocardial ischemia and ischemia/reperfusion injury in
mice (Singh et al., 2009; Ling et al., 2013). Of note, the lat-
ter work conducted by the group of Mark Anderson was the
first to perform gene expression profiling in a relevant animal
model of cardiac stress, after myocardial infarction in mice. In
this study, a CaMKII inhibitory peptide was used. Thus, potential
off target effects need to be taken into account. For instance, it
was shown that the CaMKII inhibitory peptide can also inhibit
protein kinase D (PKD) (Backs et al., 2009). Gene expression
arrays in genetic loss of functionmodels might provide important
additional information.
A possible physiological CaMKII-dependent transcriptional
effect mediated by CaMKIIδB is the activation of heat shock factor
1 (HSF-1), a transcription factor responsible for inducible heat
shock protein 70 (iHSP70) gene regulation. CaMKII is known
to phosphorylate HSF-1 at Ser-230 (Holmberg et al., 2001), and
Wei Peng and colleagues provided data suggesting that this might
be a CaMKII-dependent antiapoptotic mechanism during car-
diac ischemia and reperfusion (Peng et al., 2010). In this context,
others could show that CaMKIIδB protects from doxorubicine-
induced apoptosis, perhaps through GATA4-related expression of
the antiapoptotic bcl-2 (B-cell lymphoma 2) gene (Little et al.,
2009), although the mechanism how CaMKII induced GATA4-
dependent gene expression was not shown. Taken the central role
of GATA4 in cardiac hypertrophy and growth (Oka et al., 2006;
Heineke et al., 2007), more data are warranted to clarify the role of
GATA4 as a downstream target of CaMKII. Taken together, there
are only sparse data available on how CaMKII directly interacts
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with transcription factors, and for most factors a direct bind-
ing and phosphorylation by CaMKII is not yet shown (See also
Table 2).
In an interesting recent in vitro study, Jarkko Ronkainen
et al. describe how CaMKII potentiates the translocation of
the transcriptional repressor DREAM (downstream regulatory
element agonist modulator) into the nucleus and thereby pro-
motes DREAM-induced transcriptional repression. In their study,
the authors could show that this mechanism is involved in
CaMKII-dependent downregulation of the pore-forming α-
subunit (Cav1.2) of the L-type calcium channel (LTCC) and
postulate this to be a physiological feedback mechanism, which
enables cardiomyocytes to adjust calcium influx through the LTCC
to calcium-activated CaMKII activity (Ronkainen et al., 2011).
Another “indirect” transcriptional mechanism seems to be
mediated by an interaction between CaMKII and calcineurin A.
The phosphatase calcineurin A dephosphorylates nuclear factor
of activated T-cells (NFAT), resulting in nuclear accumulation
of NFAT and consequent activation of NFAT-dependent tran-
scriptional programs and severe cardiac hypertrophy (Molkentin
et al., 1998). In an elegant study, it was demonstrated that
cytosolic CaMKIIδC phosphorylates calcineurin A within its
calmodulin binding domain at Ser-411 and thereby inhibits its
activity (MacDonnell et al., 2009). Although the relevance of
these findings needs to be proven in vivo, this suggest that
CaMKIIδC may act as a negative modulator of calcineurin/NFAT
activity.
CaMKII AND EPIGENETIC REGULATION
Besides its direct effects on transcriptional regulators, CaMKII
regulates gene expression also by phosphorylation of proteins
of the epigenetic machinery, especially histone deacetylases
(HDACs) and in particular class II HDACs. These interesting
mechanisms were initially identified upon the observation that
class II HDACs interact with the transcription factor MEF2.
MEF2 was introduced to depend on CaMKI and CaMKIV more
than 10 years ago by the group of Eric Olson and has been
established as a critical transcription factor in cardiac remodel-
ing processes (Passier et al., 2000). MEF2 is a common target
for several hypertrophic pathways, although its precise function
in cardiac remodeling and the cardiac genes that are modu-
lated by this factor are still under investigation. MEF2 proteins
are responsive to calcium-controlled signaling pathways, such as
CaMKI, CaMKII, CaMKIV, and Calcineurin (Passier et al., 2000;
McKinsey et al., 2002; Zhang et al., 2007). Class II HDACs are
expressed in the heart and contain a MEF2 binding domain in the
N-terminal region, which is not present in other HDACs. This
N-terminal domain binds to the chaperone 14-3-3 and is then
exported from the nucleus with the consequent de-repression
of MEF2 (Backs and Olson, 2006; McKinsey, 2007; Ling et al.,
Table 2 | CaMKII-dependent regulators of cardiac transcription.




CREB Transcription factor Unknown Ser-133, Ser-142 Yes Sun et al., 1994
Activating transcription
factor 1
ATF-1 Transcription factor Unknown Ser-63 Yes Shimomura
et al., 1996
Myocyte elongation factor 2 MEF2 Transcription factor Hypertrophy/remodeling Unknown / Passier et al.,
2000
Serum response factor SRF Transcription factor Unknown Ser-103, Thr-160 Yes Fluck et al., 2000
Nuclear factor κB NF-κB Transcription factor Hypertrophy/remodeling Indirect via IκB kinase / Kashiwase et al.,
2005; Ling et al.,
2013
Histone deacetylase 4 HDAC4 Transcriptional repressor Hypertrophy/remodeling Ser-467, Ser-632 Yes Backs et al.,
2006
Histone deacetylase 5 HDAC5 Transcriptional repressor Hypertrophy/remodeling Unknown / Wu et al., 2006;
Backs et al.,
2008
GATA4 / Transcription factor Antiapoptotic Unknown / Little et al., 2009
Activation protein 1 AP-1 Transcription factor Calcium homeostasis Unknown / Mani et al., 2010





DREAM Transcriptional repressor Calcium homeostasis Unknown / Ronkainen et al.,
2011
Histone H3 H3 Histone Hypertrophy/remodeling Ser-10 Yes Awad et al., 2013
CaMKII interacts with various transcription factors, transcriptional repressors, and histone 3 and thereby influences cardiac gene expression. This interaction can
be a direct phosphorylation of Ser/Thr residues by CaMKII, indirect via other proteins (other kinases or cardiac repressors) or by unknown mechanisms. Known
phosphorylation site and proof of direct phosphorylation are indicated. CaMKII Calcium/Calmodulin-dependent kinase II.
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2013). 14-3-3 binding depends on phosphorylation of HDACs
by different kinases. For example, PKD phosphorylates all class
II HDAC family members (HDAC4, HDAC5, HDAC7, HDAC9)
(Vega et al., 2004; Harrison et al., 2006).
We found that CaMKII selectively signals to HDAC4 via bind-
ing to a unique docking site and phosphorylation of Ser-467
and Ser-632 (Backs et al., 2006) (See also Figure 2). These data
were confirmed by others and phosphorylation of HDAC4 by
CaMKII was suggested as a central mechanism in the devel-
opment of cardiac hypertrophy and remodeling (Little et al.,
2007; Zhang et al., 2007; Backs et al., 2009). HDAC5 does
not bind to CaMKII and can therefore only be regulated by
CaMKII when it is located in close proximity to HDAC4. When
HDAC5 oligomerizes with HDAC4, it can be phosphorylated and
exported in a complex with HDAC4 and CaMKII (Backs et al.,
2008). Accordingly, HDAC5 has been shown to be regulated by
CaMKII under certain conditions. The Bers lab demonstrated
that calcium in the nuclear envelope is regulated independently
from the global calcium transients that cause contraction at each
heartbeat. Interestingly, calcium release from the nuclear enve-
lope activates nuclear CaMKII, which triggers nuclear export of
HDAC5 (Wu and Bers, 2006; Wu et al., 2006). Whereas nuclear
CaMKIIδB and cytosolic CaMKIIδC exert different effects on the
phosphorylation of calcium handling proteins as the ryanodine
receptor or phospholamban and on calcium homeostasis (Zhang
et al., 2007), both isoforms lead to cytosolic accumulation of
HDAC4 and an increase in the activity of the transcription fac-
tor MEF2 (Backs et al., 2006). Nuclear CaMKIIδB phosphorylates
HDAC4 in the nucleus, leading to nucleo-cytoplasmic shuttling
of HDAC4. Activation of cytoplasmic CaMKIIδC phosphorylates
HDAC4 in the cytosol and prevents the import of HDAC4 from
the cytosol to the nucleus (Backs et al., 2006). Thus, cytoplas-
mic CaMKII is also capable to regulate transcription in addition
to its effects on excitation-contraction coupling. These findings
strongly suggested that CaMKII indirectly regulates MEF2 by dis-
sociating HDAC4 and HDAC5. However, HDAC4 binds to many
other proteins such as other transcription factors including SRF
(Davis et al., 2003), co-repressors as CtBP (C-terminal-binding
protein) (Zhang et al., 2001) but also to other chromatin modify-
ing enzymes (Zhang et al., 2002a), opening the possibility that
CaMKII exerts via cytosolic accumulation of HDAC4 broader
effects than simply activating MEF2 (Lehmann et al., 2013).
FIGURE 2 | Schematic of CaMKII-dependent epigenetic mechanisms.
(A) HDAC4 as a nodal point for CaMKII-dependent epigenetic regulation.
CaMKII binds to HDAC4 and phosphorylates HDAC4 at Ser-467 and Ser-632,
leading to nucleo-cytoplasmic shuttling of HDAC4. When located in the
nucleus, HDAC4 represses transcription factors such as MEF2, SRF, or the
co-repressor CtBP. Binding to these transcriptional regulators directs HDAC4
to specific chromatin regions. HDAC4 recruits other chromatin modifying
enzymes and direct them to the aforementioned specific chromatin regions.
This results in CaMKII/HDAC4-dependent regulation of histone methylation
(via interaction with HP1 and histone methyltransferase SUV39H1) and
deacetylation (via interaction with SMRT/N-CoR and class I HDACs).
Moreover, HDAC4 oligomerizes with HDAC5, and thereby induces 14-3-3
dependent nucleo-cytoplasmic shuttling of the HDAC4/HDAC5 complex,
leading to de-repression of HDAC4/HDAC5-dependent transcription factors.
Thus HDAC4 integrates CaMKII-dependent signals via epigenetic
mechanisms. (B) Histones (H2A, H2B, H3, and H4) assemble with DNA to
form nucleosomes. CaMKII directly phosphorylates Ser-10 in the N-terminal
region of histone 3, which is located next to Lys-9, a major site for
acetylation, and methylation. Phosphorylation at Ser-10 was suggested to
result in cardiomyocyte hypertrophy and increased chromatin binding of
CaMKII at specific gene loci reactivated during cardiac hypertrophy. CaMKII
Calcium/Calmodulin-dependent kinase II, CtBP C-terminal binding protein,
HDAC histone deacetylase, HP1 heterochromatin protein 1, MEF2 myocyte
elongation factor, N-CoR nuclear receptor co-repressor, SMRT silencing
mediator of retinoic acid and thyroid hormone receptor, and SRF serum
response factor.
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Histones are major components of chromatin and assemble
with DNA to form nucleosomes, (Jenuwein and Allis, 2001). The
N-terminal regions of histones are subjected to a variety of post-
translational modifications, including acetylation, methylation,
ubiquitination, SUMOylation, and phosphorylation (Kouzarides,
2007; Ruthenburg et al., 2007). Figure 2 summarizes important
interacting proteins of HDAC4 that direct HDAC4 to specific
chromatin regions by binding to transcription factors. Of note,
the deacetylase activity of class II HDACs is low but the bind-
ing affinity to acetylated lysines is high, suggesting that HDAC4
is mainly recruited to acetylated chromatin regions in close prox-
imity to regions where MEF2 or SRF binds (Lahm et al., 2007).
Although its deacetylase activity is low, HDAC4 binds indirectly
via the co-repressors SMRT (silencing mediator of retinoic acid
and thyroid hormone receptor) and N-CoR (nuclear receptor co-
repressor) to class I HDACs with high deacetylase activity (Fischle
et al., 2002) and via HP1 (heterochromatin protein 1) to his-
tone methyltransferases (Zhang et al., 2002a). Thus it is tempting
to speculate that CaMKII effects besides transcriptional activity
of MEF2 and SRF also class I HDAC-dependent histone acety-
lation and histone methyltransferase-dependent histone methy-
lation. Indeed, together with the Maack lab we could show that
HDAC4 controls histone methylation in a CaMKII-dependent
manner (Hohl et al., 2013). ANF and brain natriuretic peptide
(BNP) expression in failing hearts was accompanied by demethy-
lation of histone 3 at lysine 9 (H3K9) and dissociation of HP1
from the promoter regions of ANF and BNP, and this was con-
trolled byHDAC4, possibly by forming a transcriptional repressor
complex with the histone methyltransferase SUV39H1 that was
disrupted by CaMKII-induced phosphorylation of HDAC4. The
importance of the CaMKII/HDAC4/MEF2-pathway with regard
to epigenetic mechanisms in cardiac remodeling was underscored
by a recent study from the Condorelli lab (Papait et al., 2013).
The authors performed chromatin immunoprecipitation com-
bined with genomic sequencing (ChIP-Seq) and RNA sequencing
in isolated cardiomyocytes after TAC surgery and found a specific
epigenetic signature that regulated gene expression by govern-
ing the activity of promoters and enhancers related to cardiac
hypertrophy. Interestingly, they found MEF2 to be the main tran-
scription factor to orchestrate this hypertrophic gene program by
regulating the activity of transcriptional enhancers.
With regard to epigenetic mechanisms, in cardiac biologymost
attention so far was paid to histone acetylation and methyla-
tion. Histone phosphorylation is thought to be important for
cell cycle regulation and was thus not carefully studied in the
adult heart (Walter et al., 2008; Baek, 2011). Recently, it was
reported by the group of Coralie Poizat that nuclear CaMKII
activates cardiac transcription by direct binding to the chro-
matin. CaMKII was shown to phosphorylate Ser-10 of histone 3
(H3S10) which is located next to Lys-9, a major site for acety-
lation and methylation (Awad et al., 2013). Phosphorylation of
H3S10 was accompanied by hypertrophy of primary cultured car-
diomcyocytes and with increased chromatin binding of CaMKII
at specific gene loci reactivated during cardiac hypertrophy under
control of the transcription factorMEF2. These findings represent
an interesting new epigenetic mechanism governed by CaMKII.
The possibility, that ventricular remodeling can be mediated by
CaMKII-dependent chromatinmodifications opens a new avenue
of regulatory mechanisms. Important further studies are war-
ranted. ChIP-Seq studies may identify direct target genes of
CaMKII that are important for diseases processes.
SUMMARY AND OUTLOOK
CaMKII regulates not only immediate cellular functions but also
chronic processes such as ventricular remodeling leading to heart
failure. In particular, CaMKII integrates several cellular pathways
by inducing gene programs that are not understood in detail.
Here, we reviewed the yet known transcriptional and epigenetic
mechanisms by which CaMKII regulates cardiac gene expression.
However, the relative importance of the different downstream
mechanisms still needs to be clarified. Unbiased gene expres-
sion analyses and epigenetic profiling are warranted to define
the specific gene programs that contribute to phenotypic changes
induced by CaMKII.
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